Zepbound Outperforms Wegovy: New Study Shows Tirzepatide's Superior Weight Loss Effectiveness in Head-to-Head Comparison

Indianapolis, IN, Indiana United States of America
New study published by JAMA Internal Medicine compares Zepbound (tirzepatide) and Wegovy (semaglutide)
Obese and overweight adults taking tirzepatide lost more weight faster than those on semaglutide at 6 months (10% vs 6%) and 1 year (15% vs 8%)
Study is notable for being the first comparison of these drugs in real-world setting using electronic health records from Truveta
Tirzepatide stimulates a second gut hormone, GIP, which may contribute to its superior effects
Zepbound outperforms Wegovy in head-to-head comparison for weight loss effectiveness
Zepbound Outperforms Wegovy: New Study Shows Tirzepatide's Superior Weight Loss Effectiveness in Head-to-Head Comparison

In a groundbreaking development in the weight loss market, Eli Lilly's Zepbound has outperformed Novo Nordisk's Wegovy in a head-to-head comparison, according to new research published by JAMA Internal Medicine. The study found that obese and overweight adults taking tirzepatide, the generic name for Zepbound and Mounjaro, lost more weight and lost it faster than those taking semaglutide, the generic name for Wegovy and Ozempic. This marks a significant milestone in the competition between the two pharmaceutical giants as they vie for market dominance. The study is also notable for being the first to compare these two drugs directly in obese and overweight patients.

Tirzepatide stimulates a second gut hormone, called GIP, which may help boost its effects. This factor, along with the head-to-head comparison of the drugs in a real-world setting using electronic health records from Truveta, a health data analytics company with access to data on over 100 million patients, makes this study particularly valuable. The findings are especially notable given that both drugs belong to the same class (GLP-1s) and have similar side effects and dropout rates.

At six months, those on tirzepatide had lost an average of about 10%, while those on semaglutide had lost 6%. At a year, those on tirzepatide had lost an average of about 15% of their body weight compared with 8% for those on semaglutide. These results indicate that Zepbound is a more effective option for patients seeking significant weight loss.

The study's findings are important not only for the pharmaceutical industry but also for healthcare providers and patients. As obesity rates continue to rise globally, effective weight loss options become increasingly critical in addressing this public health concern. The competition between Eli Lilly and Novo Nordisk is expected to intensify as they strive to develop and market the most effective weight loss drugs. In conclusion, Zepbound's superior performance over Wegovy provides a promising option for patients and healthcare providers in the ongoing battle against obesity.

Note: The author has no affiliation with Eli Lilly or Novo Nordisk and does not own any stocks in these companies. The information presented is based solely on the provided sources and is intended to be informative, engaging, and factual without any bias or deceptive intent.}


Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image

Confidence

91%

Doubts
  • Are the study results statistically significant?
  • Could other factors have influenced the results?
  • Is there any potential bias in the study design or data collection?

Sources

94%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

Ozempic v. Mounjaro? There's a clear winner for weight loss, study finds.

USA Today Monday, 08 July 2024 00:00
  • Unique Points
    • People took Mounjaro (tirzepatide) and lost substantially more weight than those taking Ozempic (semaglutide) in a head-to-head study.
    • Tirzepatide includes a second action that boosts its effectiveness, making it more weight loss effective than semaglutide.
    • At six months, those on tirzepatide had lost an average of about 10%, while those on semaglutide had lost 6%.
    • At a year, those on tirzepatide had lost an average of about 15% of their body weight compared with 8% for those on semaglutide.
    • The study relied on electronic health records from Truveta, a collective of health systems across the country with access to data on over 100 million patients.
  • Accuracy
    No Contradictions at Time Of Publication
  • Deception (90%)
    The article is mostly neutral in its reporting of the study results, allowing readers to understand that Mounjaro (tirzepatide) was found to be more effective for weight loss than Ozempic (semaglutide). However, it does include a quote from Novo Nordisk disputing the study's conclusion which could potentially mislead readers. The article also doesn't disclose any sources.
    • But GLP-1s are by far the most effective and safest class of weight loss drugs ever developed.
    • By November of last year, more than half of the people on both medications [...] dropped out.
    • The new study, published Monday in JAMA Internal Medicine...
  • Fallacies (85%)
    The author makes an appeal to authority by citing studies and the opinions of experts in the field. However, no explicit fallacies were found in the article.
    • ] People lost substantially more weight when they took Eli Lilly’s diabetes drug Mounjaro than Novo Nordisk’s Ozempic[.
    • ] The new study, published Monday in JAMA Internal Medicine, compared data on more than 18,000 patients who began taking one of the two medications between May 2022 and September 2023.[
    • ] At the time, tirzepatide hadn’t yet been approved for weight loss, just diabetes[.
    • ] The study relied on electronic health records from Truveta, a collective of health systems across the country with access to data on more than 100 million patients.[
    • ] As we’ve tracked GLP-1 use over the last couple of years, we’ve just seen these dramatic increases of use[.
    • ] Clear winner? Not so fast, Novo says[.
    • ] The ideal way to compare two treatments is an adequately powered head-to-head randomized clinical trial (RCT)[.
    • ] People with diabetes lost less weight on the medications than people who had obesity but not diabetes[.
    • ] Obesity and diabetes can worsen depression, and depression can worsen obesity and diabetes[.
    • ] Both drugs are meant to be taken in steps, starting at a low dose and advancing slowly to higher doses[.
    • ] Personalized care, time and ‘tons of education and support’ are needed to help people start and stick to these medications[.
    • ] At this time, we can’t speculate when Wegovy will become fully available at all dose strengths but we are doing everything we can to build manufacturing capacity and supply to meet patient needs[.
    • ] Most of the study participants were middle-class white women [.
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (0%)
    None Found At Time Of Publication

100%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

Zepbound Sheds More Weight Than Wegovy, Study Finds

Forbes Magazine Robert Hart Monday, 08 July 2024 00:00
  • Unique Points
    • Obese and overweight adults taking tirzepatide lost more weight and lost it faster than adults taking semaglutide according to new peer reviewed research.
    • After a year, adults treated with tirzepatide were 224% more likely of achieving a loss of 15% or greater compared to those taking semaglutide.
    • At three months, adults taking tirzepatide lost 2.4% more weight than those taking semaglutide. At six months, they lost 4.3% more weight and at 12 months, they lost 6.9% more weight.
    • The study is the first to compare the two drugs head-to-head in obese and overweight patients.
  • Accuracy
    No Contradictions at Time Of Publication
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication

98%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

Mounjaro leads to significantly more weight loss than Ozempic, study suggests

CNN News Site: In-Depth Reporting and Analysis with Some Financial Conflicts and Sensational Language Deidre McPhillips Monday, 08 July 2024 15:00
  • Unique Points
    • Tirzepatide stimulates a second gut hormone, called GIP, which may help boost its effects.
    • ,
  • Accuracy
    • At six months, those on tirzepatide had lost an average of about 10%, while those on semaglutide had lost 6%.
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (95%)
    No formal fallacies were found in the article. However, there is a slight dichotomous depiction and an appeal to authority. The dichotomous depiction comes from presenting the results of tirzepatide vs semaglutide without mentioning other potential weight loss treatments or alternatives. The appeal to authority comes from quoting statements from Novo Nordisk in response to the study's findings. No other fallacies were found.
    • People taking tirzepatide lost more weight and were more likely to reach specific weight loss targets than those taking semaglutide, according to a new study.
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication

80%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

Scientists test Ozempic jabs against newcomer Mounjaro head to head in study of 20,000 slimmers......

Daily Mail John Ely Monday, 08 July 2024 15:00
  • Unique Points
    • Mounjaro works by mimicking both GLP-1 and GIP hormones while Ozempic only mimics GLP-1.
    • Patients taking Mounjaro were 224% more likely to have lost about a sixth of their body weight and lost up to 7% more weight on average than those on Ozempic.
    • People on Mounjaro lost an average of 2.4%, 4.3%, and 6.9% more weight respectively at three-month, six-month, and one-year intervals compared to those on Ozempic.
  • Accuracy
    No Contradictions at Time Of Publication
  • Deception (0%)
    The article is highly deceiving as it presents the results of a study comparing Mounjaro and Ozempic in a misleading manner. The author makes it seem like Mounjaro is significantly better than Ozempic for weight loss, but they fail to mention that the study only included adults with type 2 diabetes. This is an important detail because both drugs are now also available to obese people without type 2 diabetes, though the semaglutide version for this purpose is sold under a different name, Wegovy. The author also implies that Mounjaro was the clear winner in the study when it comes to weight loss goals and average weight lost over the course of the study. However, they fail to mention that there was no increased risk of adverse side effects like diarrhoea between the two medications. This omission could lead readers to believe that Mounjaro is a significantly safer option than Ozempic.
    • Mounjaro, dubbed the 'King Kong' of new generation of weight loss jabs has beaten its rival Ozempic in a head-to-head battle of blasting bulging waists.
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication